Literature DB >> 21321124

Chronic inhibition of pyruvate dehydrogenase in heart triggers an adaptive metabolic response.

Kari T Chambers1, Teresa C Leone, Nandakumar Sambandam, Attila Kovacs, Cory S Wagg, Gary D Lopaschuk, Brian N Finck, Daniel P Kelly.   

Abstract

Diabetic cardiac dysfunction is associated with decreased rates of myocardial glucose oxidation (GO) and increased fatty acid oxidation (FAO), a fuel shift that has been shown to sensitize the heart to ischemic insult and ventricular dysfunction. We sought to evaluate the metabolic and functional consequences of chronic suppression of GO in heart as modeled by transgenic mice with cardiac-specific overexpression of pyruvate dehydrogenase kinase 4 (myosin heavy chain (MHC)-PDK4 mice), an inhibitor of pyruvate dehydrogenase. Hearts of MHC-PDK4 mice were shown to exhibit an insulin-resistant substrate utilization profile, characterized by low GO rates and high FAO flux. Surprisingly, MHC-PDK4 mice were not sensitized to cardiac ischemia-reperfusion injury despite a fuel utilization pattern that phenocopied the diabetic heart. In addition, MHC-PDK4 mice were protected against high fat diet-induced myocyte lipid accumulation, likely related to increased capacity for FAO. The high rates of mitochondrial FAO in the MHC-PDK4 heart were related to heightened activity of the AMP-activated protein kinase, reduced levels of malonyl-CoA, and increased capacity for mitochondrial uncoupled respiration. The expression of the known AMP-activated protein kinase target, peroxisome proliferator-activated receptor γ coactivator-1α (PGC-1α), a master regulator of mitochondrial function and biogenesis, was also activated in the MHC-PDK4 heart. These results demonstrate that chronic activation of PDK4 triggers transcriptional and post-transcriptional mechanisms that re-program the heart for chronic high rates of FAO without the expected deleterious functional or metabolic consequences.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21321124      PMCID: PMC3064169          DOI: 10.1074/jbc.M110.217349

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  42 in total

1.  Adaptation and maladaptation of the heart in diabetes: Part II: potential mechanisms.

Authors:  Martin E Young; Patrick McNulty; Heinrich Taegtmeyer
Journal:  Circulation       Date:  2002-04-16       Impact factor: 29.690

Review 2.  Adaptation and maladaptation of the heart in diabetes: Part I: general concepts.

Authors:  Heinrich Taegtmeyer; Patrick McNulty; Martin E Young
Journal:  Circulation       Date:  2002-04-09       Impact factor: 29.690

Review 3.  The evolving diabetes burden in the United States.

Authors:  Michael M Engelgau; Linda S Geiss; Jinan B Saaddine; James P Boyle; Stephanie M Benjamin; Edward W Gregg; Edward F Tierney; Nilka Rios-Burrows; Ali H Mokdad; Earl S Ford; Giuseppina Imperatore; K M Venkat Narayan
Journal:  Ann Intern Med       Date:  2004-06-01       Impact factor: 25.391

Review 4.  Transcriptional regulatory circuits controlling mitochondrial biogenesis and function.

Authors:  Daniel P Kelly; Richard C Scarpulla
Journal:  Genes Dev       Date:  2004-02-15       Impact factor: 11.361

Review 5.  Global and societal implications of the diabetes epidemic.

Authors:  P Zimmet; K G Alberti; J Shaw
Journal:  Nature       Date:  2001-12-13       Impact factor: 49.962

6.  The cardiac phenotype induced by PPARalpha overexpression mimics that caused by diabetes mellitus.

Authors:  Brian N Finck; John J Lehman; Teresa C Leone; Michael J Welch; Michael J Bennett; Attila Kovacs; Xianlin Han; Richard W Gross; Ray Kozak; Gary D Lopaschuk; Daniel P Kelly
Journal:  J Clin Invest       Date:  2002-01       Impact factor: 14.808

7.  Lipotoxic heart disease in obese rats: implications for human obesity.

Authors:  Y T Zhou; P Grayburn; A Karim; M Shimabukuro; M Higa; D Baetens; L Orci; R H Unger
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-15       Impact factor: 11.205

8.  The myocardial contractile response to physiological stress improves with high saturated fat feeding in heart failure.

Authors:  Jessica M Berthiaume; Molly S Bray; Tracy A McElfresh; Xiaoqin Chen; Salman Azam; Martin E Young; Brian D Hoit; Margaret P Chandler
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-05-28       Impact factor: 4.733

9.  A novel mouse model of lipotoxic cardiomyopathy.

Authors:  H C Chiu; A Kovacs; D A Ford; F F Hsu; R Garcia; P Herrero; J E Saffitz; J E Schaffer
Journal:  J Clin Invest       Date:  2001-04       Impact factor: 14.808

10.  Myocardial fatty acid metabolism: independent predictor of left ventricular mass in hypertensive heart disease.

Authors:  Lisa de las Fuentes; Pilar Herrero; Linda R Peterson; Daniel P Kelly; Robert J Gropler; Víctor G Dávila-Román
Journal:  Hypertension       Date:  2003-01       Impact factor: 10.190

View more
  53 in total

Review 1.  Metabolism in cardiomyopathy: every substrate matters.

Authors:  Julia Ritterhoff; Rong Tian
Journal:  Cardiovasc Res       Date:  2017-03-15       Impact factor: 10.787

2.  Regulation of the transcription factor EB-PGC1α axis by beclin-1 controls mitochondrial quality and cardiomyocyte death under stress.

Authors:  Xiucui Ma; Haiyan Liu; John T Murphy; Sarah R Foyil; Rebecca J Godar; Haedar Abuirqeba; Carla J Weinheimer; Philip M Barger; Abhinav Diwan
Journal:  Mol Cell Biol       Date:  2015-01-05       Impact factor: 4.272

3.  Improvements in skeletal muscle strength and cardiac function induced by resveratrol during exercise training contribute to enhanced exercise performance in rats.

Authors:  Vernon W Dolinsky; Kelvin E Jones; Robinder S Sidhu; Mark Haykowsky; Michael P Czubryt; Tessa Gordon; Jason R B Dyck
Journal:  J Physiol       Date:  2012-04-02       Impact factor: 5.182

4.  Cardiac-specific deletion of acetyl CoA carboxylase 2 prevents metabolic remodeling during pressure-overload hypertrophy.

Authors:  Stephen C Kolwicz; David P Olson; Luke C Marney; Lorena Garcia-Menendez; Robert E Synovec; Rong Tian
Journal:  Circ Res       Date:  2012-06-22       Impact factor: 17.367

Review 5.  Assessing Cardiac Metabolism: A Scientific Statement From the American Heart Association.

Authors:  Heinrich Taegtmeyer; Martin E Young; Gary D Lopaschuk; E Dale Abel; Henri Brunengraber; Victor Darley-Usmar; Christine Des Rosiers; Robert Gerszten; Jan F Glatz; Julian L Griffin; Robert J Gropler; Hermann-Georg Holzhuetter; Jorge R Kizer; E Douglas Lewandowski; Craig R Malloy; Stefan Neubauer; Linda R Peterson; Michael A Portman; Fabio A Recchia; Jennifer E Van Eyk; Thomas J Wang
Journal:  Circ Res       Date:  2016-03-24       Impact factor: 17.367

Review 6.  Regulation of pyruvate metabolism in metabolic-related diseases.

Authors:  Nam Ho Jeoung; Chris R Harris; Robert A Harris
Journal:  Rev Endocr Metab Disord       Date:  2014-03       Impact factor: 6.514

7.  Oral ethinylestradiol-levonorgestrel attenuates cardiac glycogen and triglyceride accumulation in high fructose female rats by suppressing pyruvate dehydrogenase kinase-4.

Authors:  Kehinde Samuel Olaniyi; Lawrence Aderemi Olatunji
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-10-01       Impact factor: 3.000

8.  PGC-1β and ChREBP partner to cooperatively regulate hepatic lipogenesis in a glucose concentration-dependent manner.

Authors:  Kari T Chambers; Zhouji Chen; Ling Lai; Teresa C Leone; Howard C Towle; Anastasia Kralli; Peter A Crawford; Brian N Finck
Journal:  Mol Metab       Date:  2013-05-09       Impact factor: 7.422

9.  Coenzyme A-mediated degradation of pyruvate dehydrogenase kinase 4 promotes cardiac metabolic flexibility after high-fat feeding in mice.

Authors:  Christopher Schafer; Zachary T Young; Catherine A Makarewich; Abdallah Elnwasany; Caroline Kinter; Michael Kinter; Luke I Szweda
Journal:  J Biol Chem       Date:  2018-03-14       Impact factor: 5.157

10.  Metabolic inflexibility: when mitochondrial indecision leads to metabolic gridlock.

Authors:  Deborah M Muoio
Journal:  Cell       Date:  2014-12-04       Impact factor: 41.582

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.